We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

395 hedge funds and large institutions have $8.86B invested in Royalty Pharma in 2024 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 159 increasing their positions, 123 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,323% more call options, than puts

Call options by funds: $20.8M | Put options by funds: $1.47M

51% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 39

29% more repeat investments, than reductions

Existing positions increased: 159 | Existing positions reduced: 123

29% more funds holding in top 10

Funds holding in top 10: 7 → 9 (+2)

6% more capital invested

Capital invested by funds: $8.35B → $8.86B (+$508M)

4% more funds holding

Funds holding: 378 → 395 (+17)

0.21% less ownership

Funds ownership: 70.09% → 69.88% (-0.21%)

Holders
395
Holders Change
+17
Holders Change %
+4.5%
% of All Funds
5.67%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.13%
New
59
Increased
159
Reduced
123
Closed
39
Calls
$20.8M
Puts
$1.47M
Net Calls
+$19.4M
Net Calls Change
+$10.1M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$55.2M
2
Amundi
Amundi
France
+$45.1M
3
Deutsche Bank
Deutsche Bank
Germany
+$37.7M
4
Charles Schwab
Charles Schwab
California
+$30.6M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$26.8M

Top Sellers

1
JP Morgan Chase
JP Morgan Chase
New York
-$179M
2
UE
Unisphere Establishment
Liechtenstein
-$132M
3
Morgan Stanley
Morgan Stanley
New York
-$84.6M
4
Aberdeen Group
Aberdeen Group
United Kingdom
-$30M
5
Invesco
Invesco
Georgia
-$28.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
OMC
126
Overbrook Management Corp
New York
$3.99M -$1.65M -59,504 -30%
APM
127
Advanced Portfolio Management
New York
$3.96M -$2.77M -100,000 -42%
Allspring Global Investments
128
Allspring Global Investments
North Carolina
$3.79M -$4.9M -176,980 -57%
MNA
129
Manning & Napier Advisors
New York
$3.78M -$1.73M -62,289 -32%
Mackenzie Financial
130
Mackenzie Financial
Ontario, Canada
$3.75M +$3.41M +123,066 +1,276%
Kovitz Investment Group Partners
131
Kovitz Investment Group Partners
Illinois
$3.34M -$1.4M -50,665 -30%
ASRS
132
Arizona State Retirement System
Arizona
$3.11M +$161K +5,800 +6%
CIBC Private Wealth Group
133
CIBC Private Wealth Group
Georgia
$3.11M -$1.05K -38 -0%
FDCDDQ
134
Federation des caisses Desjardins du Quebec
Quebec, Canada
$3.07M +$35.6K +1,286 +1%
SF
135
Synovus Financial
Georgia
$2.95M -$3.28M -118,379 -53%
Aberdeen Group
136
Aberdeen Group
United Kingdom
$2.93M -$30M -1,083,657 -91%
Teacher Retirement System of Texas
137
Teacher Retirement System of Texas
Texas
$2.92M +$424K +15,295 +17%
TAF
138
Tredje AP-fonden
Sweden
$2.9M – – –
Nomura Asset Management
139
Nomura Asset Management
Japan
$2.88M – – –
VanEck Associates
140
VanEck Associates
New York
$2.78M +$1.77M +64,057 +171%
ERSOT
141
Employees Retirement System of Texas
Texas
$2.77M – – –
APF
142
Alaska Permanent Fund
Alaska
$2.67M – – –
IMRF
143
Illinois Municipal Retirement Fund
Illinois
$2.67M +$851K +30,740 +48%
SAM
144
Simplify Asset Management
Nevada
$2.66M +$1.05M +37,878 +67%
BPAMU
145
BTG Pactual Asset Management US
New York
$2.57M +$2.52M +90,941 New
TI
146
Trexquant Investment
Connecticut
$2.53M +$1.76M +63,487 +246%
EGM
147
Engineers Gate Manager
New York
$2.5M +$1.05M +38,011 +76%
CUAMC
148
China Universal Asset Management Company
China
$2.44M +$920K +33,206 +63%
FAF
149
Fjarde Ap-fonden
Sweden
$2.41M +$2.36M +85,250 New
OAC
150
OMERS Administration Corp
Ontario, Canada
$2.29M – – –
4 5
6
7 8

RPRX Hedge Fund Activity: Q3 2024 in Review

395 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2024, worth a combined $8.86B — up 6.1% from $8.35B a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new RPRX positions and 39 closed out — a net gain of 20 holders — while 159 added to existing stakes and 123 trimmed.

The largest buyer was Millennium Management, adding an estimated $55.2M. The largest seller was JP Morgan Chase, cutting an estimated $179M.

  • 395 institutional investors held Royalty Pharma (RPRX) as of Q3 2024, up from 378 in Q2 2024.
  • Funds reported $8.86B of Royalty Pharma stock for Q3 2024, up 6.1% quarter-over-quarter.
  • 59 funds opened new Royalty Pharma positions in Q3 2024 and 39 closed out, a net change of +20 holders.
  • The largest Royalty Pharma buyer in Q3 2024 was Millennium Management, an estimated $55.2M added.
  • The largest Royalty Pharma seller in Q3 2024 was JP Morgan Chase, an estimated $179M sold.

Based on aggregated 13F filings for Q3 2024.